Stay updated with breaking news from Gamida Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FDA approves Omisirge (omidubicel-onlv), a nicotinamide modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery time of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection following stem cell transplantation.
Omisirge is approved by the FDA as a new donor source for allogeneic stem cell transplant Global, randomized Phase 3 clinical trial showed faster neutrophil recovery and reduced bacterial and... | April 17, 2023
The FDA has approved omidubicel-onlv (Omisirge) to quicken the recovery of neutrophils in the body and reduce the risk of infection in adults and pediatric patients aged 12 years and older with blood cancers who are slated to undergo umbilical cord blood transplantation after a myeloablative conditioning regimen.
/PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based...
Chronic health conditions, including heart disease, neurological disorders, cancer, respiratory illnesses, stroke, and cardiovascular disorders, are...